DTI Abnormalities Related to Glioblastoma: A Prospective Comparative Study with Metastasis and Healthy Subjects

Youssef El Ouadih 1,2, Bruno Pereira 3,4*, Julian Biau 4, Béatrice Claise 1, Rémi Chaix 1, Pierre Verrelle 4,5, Toufik Khalil 1, Xavier Durando 4 and Jean-Jacques Lemaire 1,*

Abstract: (1) Background: Glioblastoma multiforme (GBM) shows complex mechanisms of spreading of the tumor cells, up to remote areas, and little is still known of these mechanisms, thus we focused on MRI abnormalities observable in the tumor and the brain adjacent to the lesion, up to the contralateral hemisphere, with a special interest on tensor diffusion imaging informing on white matter architecture; (2) Material and Methods: volumes, macroscopic volume (MV), brain-adjacent-tumor (BAT) volume and abnormal color-coded DTI volume (aCCV), and region-of-interest samples (probe volumes, ipsi, and contra lateral to the lesion), with their MRI characteristics, apparent diffusion coefficient (ADC), fractional anisotropy (FA) values, and number of fibers (DTI fiber tracking) were analyzed in patients suffering GBM (n = 15) and metastasis (n = 9), and healthy subjects (n = 15), using ad hoc statistical methods (type I error = 5%); (3) Results: GBM volumes were larger than metastasis volumes, aCCV being larger in GBM and BAT ADC was higher in metastasis, ADC decreased centripetally in metastasis, FA increased centripetally either in GBM or metastasis, MV and BAT FA values were higher in GBM, ipsi FA values of GBM ROIs were higher than those of metastasis, and the GBM ipsi number of fibers was higher than the GBM contra number of fibers; (4) Conclusions: The MV, BAT and especially the aCCV, as well as their related water diffusion characteristics, could be useful biomarkers in oncology and functional oncology.

Keywords: glioblastoma; metastasis; infiltration; MRI; DTI; tractography; brain adjacent to tumor; diffusion; anisotropy; biomarker

1. Introduction

The treatment of high grade glioma, and particularly resection, is still challenging due to its well-known infiltrative nature [1–4] and the presence of inconspicuous, remote, tumor cells [5]. A multicellular network relying on microtubes could support the invasion and proliferation characteristics of this widespread disease [6]. Pioneering works have also shown that glioblastoma multiforme (GBM) growth appears typically along white matter (WM) tracts [7]. Phenotypically, the macroscopic tumor volume is still accepted, notably for GBM, as the volume limited by the contrast enhanced boundary on magnetic resonance imaging (MRI) [8], which serves to define the gross tumor volume for radiotherapy [9], and to which is added the brain adjacent to tumor (BAT) [10]. In GBM, MRI spectroscopy
features of BAT, high choline/N-acetyl-aspartate ratio and choline/creatinine ratio, argue for tumor invasion [11]. Histologically the tumor cell density decreases up to several centimeters from the macroscopic tumor volume [12]. In current clinical practice, the BAT can be referred to as the region adjacent to the gross tumor volume and which contains signal abnormalities on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, and the limit of the BAT serves as the definition of the clinical target volume (CTV) in radiotherapy [9]. Diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI) also revealed signal abnormalities in the BAT, and the nature of lesions of white matter fascicles is multiple such as infiltration, disruption, cellular and vasogenic oedema, and displacement [13,14]. Analysis of metrics of diffusion parameters in the BAT have shown: (1) fractional anisotropy (FA) of high grade gliomas is higher than for metastasis and conversely for the mean diffusivity (MD) [15]; nevertheless, it was also found that FA is lower in BAT than outside and inversely correlated to the degree of cell invasion [16]; (2) diffusion values (apparent diffusion coefficient, ADC; signal intensity on DWI) in the BAT are high in GBM, and higher than for metastasis [17]; (3) relative anisotropy in the normal T2-weighted zone is reduced and could be more specific for GBM than for metastasis and low grade glioma [18]; (4) in high grade gliomas, FA decreases and ADC increases in BAT, which is sometimes apparently normal in routine MRI [19]; (5) FA values are reduced in apparently normal and pathologic corpus callosum of patients with GBM [20]. The study of DTI fiber density in grades II and III gliomas have shown that high fiber density values are inversely correlated with the tumor cell count and infiltration, in the macroscopic tumor volume but not at its border [21]. In the GBM BAT, the DTI fiber density seems correlated with the mean FA value, which is reduced relative to the homologous contralateral region [22]. Thus, the detailed MRI analysis of the BAT is of upmost importance, as it enables the detection of subtle abnormalities, which are not specific to precise lesioning mechanisms. The growing interest in artificial intelligence methods enabling the detection of tumors on medical imaging, and the importance of optimal topographically directed molecular analysis of tissue and of planning and follow-up strategies of treatments, impose the possibility of refining our understanding of the macroscopic phenotypic definition of GBM and its invasiveness [23–26].

In that respect, we aimed to study prospectively diffusion related parameters of MRI datasets of two series of patients suffering GBM and metastasis, and of a control group of healthy subjects. We compared the values of parameters in the macroscopic tumor volume (MV), the BAT volume, and the abnormal DTI brain volume around the BAT. The abnormal DTI brain volume was determined on color-coded DTI maps that reveal the microarchitecture of the white matter and was named aCCV (abnormal color-coded volume). The aCCV appears “normal” in conventional imaging that shows the MV and the BAT; this latter is still frequently caricatured as “oedema volume” in the clinical field. The metastatic lesions were chosen for comparison with GBM because most are restrained with millimetric invasion [27,28], and as such is frequently used as the opposite model of infiltration of gliomas (see above).

2. Materials and Methods

2.1. Population

Thirty-nine subjects were enrolled ( monocentric) from March 2015 to December 2018 (Institutional Review Board approval). The inclusion criteria were: age > 18 years; no history of inflammatory or degenerative brain disease; patients with unilateral supra-tentorial tumor and a Karnofsky index > 60, and up to 3 unilateral supra-tentorial metastases. All subjects underwent an MRI exam. They all had standard corticoid and anti-epileptic oral treatment since their admission. Two patients were excluded after MRI protocol showing more than three metastases. The histopathological diagnosis after oncologic multidisciplinary meeting, specified the lesions, GBM or metastasis, enabling the inclusion of 24 patients: 15 cases of GBM, mean age = 66.6 ± 9.2 years, 9 males; 9 cases of metastases, mean age = 63.7 ± 11.0 years, 5 males. The control group consisted in 15 healthy subjects
with a mean age of 62.7 ± 6.4 years, 7 males comparable to the patients. Demographics (15 GBM + 9 metastasis; 15 healthy subjects) and tumoral characteristics (24 patients) are in Table 1.

Table 1. Characteristics of glioblastoma (GBM) and metastasis groups of patients (biopsy = stereotactic biopsy; resection = surgical tumor resection).

| GBM                   | Metastasis                          |
|-----------------------|-------------------------------------|
| Age                  | Gender | Location                  | Symptoms                     | Tumor Sample |
| 70                    | M      | occipital (left)          | memory disorder              | biopsy       |
| 70                    | M      | anterior cingulate (left) | cognitive disorder, contralateral motor paresis | biopsy       |
| 67                    | M      | fronto-temporo-insular (left) | frontal syndrome, aphasia, contralateral motor paresis | biopsy       |
| 71                    | M      | fronto-callosal (right)   | frontal syndrome             | resection    |
| 63                    | M      | temporal (left)           | headache, aphasia, contralateral motor paresis | resection    |
| 67                    | F      | occipital (right)         | headache, lateral homonym hemianopsia | biopsy       |
| 66                    | F      | tempo-insular (right)     | contralateral motor paresis  | resection    |
| 55                    | M      | tempo-insular (left)      | behavior disorder, aphasia, contralateral facial paresis | biopsy       |
| 61                    | F      | anterior cingulate (right) | contralateral motor paresis  | biopsy       |
| 65                    | M      | temporal (right)          | headache, contralateral facial paresis | resection    |
| 78                    | M      | fronto-temporo-insular (left) | frontal syndrome, aphasia, contralateral motor paresis | biopsy       |
| 75                    | F      | occipital (right)         | headache, lateral homonym hemianopsia | resection    |
| 49                    | F      | frontal (left)            | aphasia                      | resection    |
| 85                    | M      | tempo-insular (left)      | frontal syndrome, aphasia    | biopsy       |
| 57                    | F      | frontal (right)           | memory disorder, contralateral facial paresis | resection    |

| Age                  | Gender | Location                  | Symptoms (Cancer)            | Tumor Sample |
|-----------------------|--------|---------------------------|------------------------------|--------------|
| 78                    | M      | parventricular trigone (left) | inaugural (lung)            | biopsy       |
| 55                    | M      | parietal (right)          | headache (neuroendocrine)    | resection    |
| 71                    | M      | parietal (right)          | contralateral motor paresis (kidney) | resection    |
| 70                    | F      | temporal and parietal (right) | contralateral motor paresis (lung) | resection    |
| 64                    | F      | precentral (left)         | contralateral motor paresis (lung) | resection    |
| 43                    | M      | precentral (right)        | contralateral motor paresis (lung) | resection    |
| 59                    | M      | temporal (left)           | inaugural seizure (lung)     | resection    |
| 75                    | M      | frontal (left)            | headache, contralateral motor paresis (lung) | resection    |
| 59                    | F      | frontal (left)            | aphasia                      | resection    |

2.2. MRI

All MRI were performed on 3-Tesla machines (Magnetom 3T, Siemens AG, Munich, Germany; Discovery MR750, General Electric, Milwaukee, WI, USA) with a 32-channel head coil following a routine clinical protocol: T1-weighthed, T1-weigheted enhanced (except for healthy subject), T2-weigheted and FLAIR sequences, and a 20-direction DTI sequence. The images characteristics were: field of view = 240 mm; matrix 512 × 512; 3D T1, repetition time (TR) = 8.8 ms, echo time (TE) = 3.5 ms, voxel size = 0.469 mm side, slice thickness = 1.4 mm; axial T2 axial, Spin Echo, TR = 9000 ms, TE = 80 ms, voxel size = 0.469 mm side, slice thickness = 4 mm; sagittal 3D FLAIR, TR = 9000 ms, TE = 141 ms, voxel size = 0.5 mm side, slice thickness = 1 mm; DTI, TR = 7000 ms, TE = 81 ms, matrix 256 × 256, voxel size = 1 mm side, slice thickness = 3.5 mm, b = 1000 s/mm². Color-coded maps were built (Iplan Stereotaxy 3.0.2; BrainLab; München, Germany) from DTI data sets.

2.3. MRI Objects

MRI objects consisted in three volumes, manually contoured (slice by slice) and three ROIs positioned manually. This was realized after co-registration of image datasets and alignment along the anterior—posterior commissure (AC-PC) plan easing the visual comparisons (Iplan Stereotaxy 3.0.2; BrainLab; idem, Germany).

The tumoral lesion was segregated into three volumes, MV, BAT, and aCCV. The MV was defined on the 3D T1-enhanced sequence, the BAT on the 3D FLAIR and B0 diffusion sequences (hypersignal; excluding MV), and the aCCV on the color-coded DTI maps (excluding BAT). The aCCV was defined by comparison between the ipsilateral
(where the lesion was) and the contralateral hemispheres, as well as the healthy subject data sets if necessary.

We also placed region-of-interest samples, ROIs (diameter, 10 mm; thickness, 3.5 mm), in the contralateral frontal corona radiata, 10 mm above the lateral ventricle (CR-contra), and in fascicles of the white matter of the aCCV where we observed the brightest abnormal hue (highest abnormality; WMf-ipsi) and in the contralateral corresponding region (that visually fitted at best; WMf-contra). In the healthy subjects, we placed CR ROIs bilaterally (CR-right; CR-left). The MRI objects are summarized in Figures 1–3.

Figure 1. MRI objects schematized on a simplified axial MRI slice (ventricles in gray): (1) volumes, the macroscopic volume (MV), the brain adjacent to tumor (BAT) and the abnormal color-coded volume (aCCV); (2) ROIs in the corona radiata (CR-contra) and white matter fascicles (WMf), ipsi- and contra-lateral to the lesion.

Figure 2. Manual contouring of the macroscopic volume (MV, orange), the BAT volume (blue) and the abnormal color-coded volume (aCCV, yellow) on axial MRI of GBM ((A); patient 11; left GBM) and metastasis ((B); patient 3; right metastasis) cases; left column, 3D T1-enhanced sequence; intermediate column, B0 diffusion weighted sequence; right column, color-coded DTI map.
We computed the volumes of MV, BAT, and aCCV (cm³), the mean apparent diffusion coefficient (ADC; 10⁻³ x mm²/s; the higher value, the higher water-molecule diffusion) and the fractional anisotropy (FA; from 0, isotropic diffusion, to 1, anisotropic diffusion) values of the MRI objects; volumes and ROIs of the 24 patients; only the ROIs for the 15 healthy subjects. For the GBM group, we also calculated mean ADC values of a sample (as random-effect). A Sidak’s type I error correction was applied for multiple comparisons.

Continuous data (i.e., volumes, ADC, FA, number of fibers, MV, BAT, aCCV, ipsi and CR-contra, WMf) were expressed as mean and standard deviation according to statistical distribution. The assumption of normality was assessed using the Shapiro–Wilk test. The comparisons between independent groups (GBM vs. metastasis vs. HS) were carried out using ANOVA or Kruskal-Wallis test when the assumptions of the ANOVA were not met. The homoscedasticity assumption was studied by using Bartlett’s test. When appropriate (omnibus p-value less than 0.05), post-hoc tests for two by two comparisons were performed to take into account multiple comparisons, respectively, Tukey-Kramer after ANOVA and Dunn after Kruskal-Wallis. For comparisons concerning correlated data (i.e., when several measures for a same patient were collected: volumes and ROIs), random-effects models (i.e., mixed linear regression) were used to model between and within subject variability (as random-effect). A Sidak’s type I error correction was applied for multiple comparisons.

Figure 3. 3D rendering (superior view) of the macroscopic volume (MV, orange), the BAT volume (light blue) and the abnormal color-coded volume (aCCV, light yellow) within the brain volume (same patients of the Figure 2; (A), GBM; (B), metastasis); fascicles computed (fiber tracking DTI) from WMf-ipsi and WMf-contra are embedded.
The normality of residuals from these models was studied as aforementioned. When appropriate, a logarithmic transformation was applied. Statistical analyses were performed using Stata software, Version 15 (StataCorp, College Station, TX, USA). The tests were two-sided with a type I error set at 5%

3. Results

The results are synthesized in Table 2.

Table 2. Values of MRI-object related parameters of the glioblastoma (GBM; GBM5 * see text), metastasis, and healthy subject (HS) groups.

| MRI Objects       | GBM (GBM5 *) | Metastasis | HS       | Difference |
|-------------------|--------------|------------|----------|------------|
|                   | Mean   | SD     | Mean   | SD     | Mean   | SD     | p Value |
| Volumes (cm³)     |        |        |        |        |        |        |         |
| MV                | 47.12  | 28.44 | 12.96  | 17.61 | n.a.   | n.a.   | 0.0032  |
| BAT               | 70.65  | 42.01 | 75.98  | 73.93 | n.a.   | n.a.   | 0.6983  |
| aCCV              | 176.49 | 74.21 | 44.80  | 44.73 | n.a.   | n.a.   | 0.0006  |
| mean ADC value    |        |        |        |        |        |        |         |
| (10⁻³ x mm²/s)    |        |        |        |        |        |        |         |
| MV                | 1.726  | *      | 0.527  | *      | 1.539  | 0.287  | n.a.   | 0.4634  |
| BAT               | 1.093  | *      | 0.527  | *      | 1.504  | 0.158  | n.a.   | 0.0196  |
| aCCV              | 0.911  | *      | 0.088  | *      | 0.920  | 0.103  | n.a.   | 0.9469  |
| mean FA value     |        |        |        |        |        |        |         |
|                   |        |        |        |        |        |        |         |
| ROIs              |        |        |        |        |        |        |         |
| mean ADC value    |        |        |        |        |        |        |         |
| (10⁻³ x mm²/s)    |        |        |        |        |        |        |         |
| CR-contra         | 0.708  | *      | 0.343  | *      | 0.722  | 0.220  | n.a.   | 0.2527  |
| WMf-ipsi          | 0.840  | *      | 0.071  | *      | 0.817  | 0.056  | n.a.   | 0.5485  |
| CR-right          | 0.849  | *      | 0.059  | *      | 0.797  | 0.046  | n.a.   | 0.1615  |
| CR-left (CR-L)    | n.a.   | n.a.   | n.a.   | n.a.   | 0.801  | 0.032  | n.a.   |         |
| mean FA value     |        |        |        |        |        |        |         |
|                   |        |        |        |        |        |        |         |
| 3.1. Tumoral Related Volumes

The mean MV and aCCV of GBM were larger than those of metastasis. In GBM, the mean MV and BAT were comparable ($p = 0.135$) but the mean aCCV was larger than MV ($p < 0.001$) and BAT ($p < 0.001$). In metastasis, the mean BAT was larger than MV ($p = 0.001$) but the other volumes were comparable (aCCV vs. BAT, $p = 0.100$; aCCV vs. MV, 0.107).

The mean ADC value of BAT was higher in metastasis than in GBM. In GBM, the mean ADC value of BAT and aCCV were lower than MV (respectively, $p = 0.01$ and <0.001), but the mean ADC values of aCCV and BAT were comparable ($p = 0.4566$). In metastasis, the mean ADC value of aCCV was lower than MV ($p < 0.001$) and BAT ($p < 0.001$).

The mean FA values of MV and BAT were higher in GBM than in metastasis. In GBM and metastasis, the mean FA values increased from MV to BAT then aCCV ($p < 0.001$ for MV vs. BAT, BAT vs. aCCV and MV vs. aCCV).
3.2. ROIs

The mean ADC and FA CR-ROIs values of healthy controls were comparable between the right and left hemispheres ($p = 0.99$), as well as CR-contra of GBM and metastasis. In GBM and metastasis, the mean ADC values of WMf-ipsi were comparable to WMf-contra and to CR-contra (GBM, WMf-contra, $p = 0.408$; GBM, CR-contra, $p = 0.310$; metastasis, WMf-contra, $p = 0.257$; metastasis, CR-contra, $p = 0.286$).

In GBM, the mean FA values of WMf-ipsi were higher than WMf-contra ($p = 0.003$) and WMf-contra was comparable to CR-contra ($p = 0.834$). In metastasis, the mean FA values of WMf-ipsi were comparable to WMf-contra ($p = 0.319$) and to CR-contra ($p = 0.209$). The number of fibers (ipsi and contra) were comparable between GBM and metastasis. In GBM, the number of fibers of the WMf-ipsi was higher than that of the WMf-contra ($p = 0.039$), whereas it was comparable in metastasis ($p = 0.086$).

4. Discussion

Based on our MRI-tissue-volume analysis, in GBM we found that aCCV volume was larger than MV and BAT volumes, which were larger than those of metastasis. In metastasis, BAT volume was comparable to aCCV, and larger than MV. Thus, it is as if the GBM MV is larger and associated with two adjacent coronas, BAT and beyond aCCV, whereas metastasis has smaller MV and is surrounded by relatively similar BAT and aCCV volumes. The wider volumetric extension and larger volumes in GBM, relative to metastasis, is consistent with sparse data [30–32]. We also found that proton-diffusion features were common to GBM and metastasis: the mean-ADC value decreases, centripetally, progressively from MV to aCCV, and conversely for the mean-FA value, altogether with the centripetal lowering of lesioning processes. The mean ADC values of GBM and metastasis were above normal values, ranging from 0.71 to $0.90 \times 10^{-3}$ mm$^2$/s [33–36] that include the values observed in our group of healthy subjects (CR, ROIs). They reached almost normal values in the aCCV. The disorganization of tissue architecture, i.e., of the fascicular organization of fiber bundles, seems less severe in BAT of GBM. Indeed, in GBM, MV and BAT FA values were lower than in metastasis, and BAT mean-FA values were about 0.20, which is a normal threshold value usually considered for fiber tracking of fascicles in white matter [37–39]. Normal FA values range from 0.4 to 0.8 [40,41], and depend on the white matter architecture, i.e., the 3D organization of fascicles and the conservation of axonal membranes [42], and at a lesser extent on an MRI machine [43]. Thus, the core of the structural disorganization is maximal (highest ADC; lower FA) within the MV, where the necrosis developed, and which is surrounded by an intense immune reaction [44] and noticeably the angiogenesis identified on CT-Scan, MRI, and ultrasound [45,46]. In GBM, the diffusion decreased between MV and either BAT or aCCV, which had comparable mean ADC values likely because of the infiltrative nature of the lesion [16]. In metastasis, we found the centrifugal gradient of reduction of ADC values, from MV to BAT then aCCV. In BAT, the mean ADC value was higher in metastasis than in GBM, in line with another work [47], showing a higher water diffusivity within the close vicinity of macroscopic tumoral volume where metastasis develop a complex peritumoral edema [48,49]. The Figure 4 synthesizes results.
Figure 4. Artistic drawing of MRI characteristics of GBM (A), and metastasis (B): the highest ADC value is in MV; the BAT ADC value is higher in metastasis; a high FA value is in GBM aCCV; fascicles are depicted as white/black ribbons, structurally lesioned in red, and functionally harmed in orange.

ROIs data showed that the white matter contralateral to the lesion (CR-contra), either in GBM or metastasis, had normal ADC and FA values (CR-R&L). The mean ADC values, contra- and ipsi-lateral, were also comparable, either in GBM or metastasis. Yet, we found a specific anisotropic pattern of GBM, i.e., ipsilateral high anisotropy coupled with a high number of fiber bundles, while the numbers of fibers were comparable between GBM and metastasis. These findings rely on precise positioning of topographically comparable regions, enabling a fair comparison between mean-FA values. Altogether, a high number of fiber and high mean FA, should reflect a densification of axons, compacted (Figure 3), with reorientation of bundles. This could also reflect the presence of long distance invasion and/or its consequence, such as fascicle disorganization or edema, knowing that water diffusion relies on the size of extracellular space but also on water channels [50,51]. The intime mechanisms must be further determined. This particular aspect, i.e., focal high-anisotropy, completes patterns with normal or low anisotropy, reorientation of fibers and diffusion modifications [52,53]. The impact of such modifications during the exploration of brain function, i.e., the functional neuro-oncology, notably intraoperatively in the vicinity of glioma, regardless of the method such as electrostimulation during awake surgery and/or fiber tracking navigation under general anesthesia, must be explored. New fiber tracking techniques could be helpful to refine the analysis [54]. Interestingly, high ADC and low FA values seem reversible following radiation therapy combined with gefitinib or tipifarnib in high grade glioma of the brainstem in pediatric patients [55].

Globally our results detail the information harvested by the analysis of normal-appearing white matter (NAWM) reporting low FA and ADC values, bearing in mind that NAWM is less restrictive than aCCV as it includes the whole brain with a normal aspect on contrast-enhanced-T1 and FLAIR [13,56], i.e., the whole brain around the BAT.
5. Conclusions

In conclusion, our findings highlight structural abnormalities revealed by DTI, which seems a promising in vivo modality of brain tumor exploration [57], accompanied by a careful interpretation of the information provided [58]. The MV, BAT, and especially the aCCV based on normalized color-coded maps, could be useful biomarkers in oncology and functional oncology. For example, they could guide the determination of spots for biopsies and study of molecular markers [59], and refine the individualization of CTV [60]. In the clinical field, before biopsy, the MRI volume features could also assist in distinguishing between GBM and metastasis, which is sometimes difficult. Further progress in radiomics [24,61–63] and data analysis [64] should enable the optimization of the analysis of this information. The presence of focal high-anisotropy areas in the aCCV opens a new window on the GBM disease that impacts, functionally and structurally, remote brain areas.

Author Contributions: Conceptualization, J.-J.L. and Y.E.O.; methodology, B.P. and J.-J.L.; validation, J.B., B.C., R.C., T.K. and X.D.; formal analysis, Y.E.O., B.P. and J.-J.L.; investigation, Y.E.O., J.B., B.C., R.C., T.K. and X.D.; resources, B.C. and Y.E.O.; data curation, Y.E.O. and B.C.; writing—original draft preparation, Y.E.O., J.-J.L. and B.P.; writing—review and editing, Y.E.O., J.-J.L., J.B., B.C., R.C., P.V., T.K. and X.D.; visualization, Y.E.O., B.P. and J.-J.L.; supervision, J.-J.L.; project administration, B.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of CHU Clermont-Ferrand (IRB approval, CPP 18/587).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study, or their representative.

Data Availability Statement: Data available on request due to restrictions e.g., privacy or ethical.

Acknowledgments: We thank Céline Botella, neurosurgeon, who participated to the starting phase, and the teams of the pathological anatomy and the radiological departments for their supports.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO Classification of Tumours of the Central Nervous System. *Acta Neuropathol.* 2007, 114, 97–109. [CrossRef] [PubMed]
2. Perry, A.; Wesseling, P. Histologic Classification of Gliomas. *Handb. Clin. Neurol.* 2016, 134, 71–95. [CrossRef] [PubMed]
3. Wesseling, P.; Capper, D. WHO 2016 Classification of Gliomas. *Neuropathol. Appl. Neurobiol.* 2018, 44, 139–150. [CrossRef]
4. Kelly, P.J.; Daumas-Dupont, C.; Kispert, D.B.; Kall, B.A.; Scheithauer, B.W.; Illig, J.J. Imaging-Based Stereotaxic Serial Biopsies in Untreated Intracranial Glial Neoplasms. *J. Neurosurg.* 1987, 66, 865–874. [CrossRef]
5. Sahm, F.; Capper, D.; Jeibmann, A.; Habel, A.; Paulus, W.; Troost, D.; von Deimling, A. Addressing Diffuse Glioma as a Systemic Brain Disease with Single-Cell Analysis. *Arch. Neurol.* 2012, 69, 523–526. [CrossRef]
6. Osswald, M.; Jung, E.; Sahm, F.; Solecki, G.; Venkataramani, V.; Blaes, J.; Weil, S.; Horstmann, H.; Wiestler, B.; Syed, M.; et al. Brain Tumour Cells Interconnect to a Functional and Resistant Network. *Nature* 2015, 528, 93–98. [CrossRef]
7. Scherer, H.J. A critical review: The pathology of cerebral gliomas. *J. Neurol. Psychiatry* 1940, 3, 147–177. [CrossRef] [PubMed]
8. Rees, J.H.; Smirniotopoulos, J.G.; Jones, R.V.; Wong, K. Glioblastoma Multiforme: Radiologic-Pathologic Correlation. *Radiographics* 1996, 16, 1413–1438; quiz 1462–1463. [CrossRef]
9. Burnet, N.G.; Thomas, S.J.; Burton, K.E.; Jeffries, S.J. Defining the Tumour and Target Volumes for Radiotherapy. *Cancer Imaging* 2004, 4, 153–161. [CrossRef]
10. Schiffer, D.; Annovazzi, L.; Caldera, V.; Mellai, M. On the Origin and Growth of Gliomas. *Anticancer Res.* 2010, 30, 1977–1998.
11. Yan, J.-L.; Li, C.; Boonzaier, N.R.; Fountain, D.M.; Larkin, T.J.; Matys, T.; van der Hoorn, A.; Price, S.J. Multimodal MRI Characteristics of the Glioblastoma Infiltration beyond Contrast Enhancement. *Ther. Adv. Neurol. Disorder.* 2019, 12, 1756286419844664. [CrossRef] [PubMed]
12. Yamahara, T.; Numa, Y.; Oishi, T.; Kagavuchi, T.; Seno, T.; Asai, A.; Kawamoto, K. Morphological and Flow Cytometric Analysis of Cell Infiltration in Glioblastoma: A Comparison of Autopsy Brain and Neuroimaging. *Brain Tumor. Pathol.* 2010, 27, 81–87. [CrossRef] [PubMed]
13. Price, S.J.; Gillard, J.H. Imaging Biomarkers of Brain Tumour Margin and Tumour Invasion. *Br. J. Radiol.* 2011, 84, S159–S167. [CrossRef] [PubMed]

14. Watanabe, M.; Tanaka, R.; Takeda, N. Magnetic Resonance Imaging and Histopathology of Cerebral Gliomas. *Neuroradiology* 1992, 34, 463–469. [CrossRef] [PubMed]

15. Jiang, R.; Du, F.-Z.; He, C.; Gu, M.; Ke, Z.-W.; Li, J.-H. The Value of Diffusion Tensor Imaging in Differentiating High-Grade Gliomas from Brain Metastases: A Systematic Review and Meta-Analysis. *PLoS ONE* 2014, 9, e112580. [CrossRef] [PubMed]

16. Deng, Z.; Yan, Y.; Zhong, D.; Yang, G.; Tang, W.; Li, F.; Xie, B.; Liu, B. Quantitative Analysis of Glioma Cell Invasion by Diffusion Tensor Imaging. *J. Clin. Neurosci.* 2010, 17, 1507–1506. [CrossRef] [PubMed]

17. Kolakshyapati, M.; Adhibikari, R.B.; Karlowee, V.; Takayasu, T.; Nosaka, R.; Amatya, V.J.; Takeshima, Y.; Akiyama, Y.; Sugiyama, K.; Kurisu, K.; et al. Nonenhancing Peritumoral Hyperintense Lesion on Diffusion-Weighted Imaging in Glioblastoma: A Novel Diagnostic and Specific Prognostic Indicator. *J. Neuropsych.* 2017, 128, 667–678. [CrossRef]

18. Price, S.J.; Burnet, N.G.; Donovan, T.; Green, H.A.L.; Peña, A.; Antoun, N.M.; Pickard, J.D.; Carpenter, T.A.; Gillard, J.H. Diffusion Tensor Imaging of Brain Tumours at 3T: A Potential Tool for Assessing White Matter Tract Invasion? *Clin. Radiol.* 2003, 58, 455–462. [CrossRef]

19. Won, Y.J.; Chung, C.K.; Kim, C.H.; Park, C.-K.; Koo, B.-B.; Lee, J.-M.; Jung, H.-W. White Matter Change Revealed by Diffusion Tensor Imaging in Gliomas. *Brain Tumor Res. Treat.* 2016, 4, 100–106. [CrossRef]

20. Kallenberg, K.; Goldmann, T.; Menke, J.; Strik, H.; Bock, H.C.; Stockhammer, F.; Buhk, J.H.; Frahm, J.; Dechent, P.; Knauth, M. Glioma Infiltration of the Corpus Callosum: Early Signs Detected by DTI. *J. Neurooncol.* 2013, 112, 217–222. [CrossRef]

21. Stadlbauer, A.; Hammes, T.; Grummich, P.; Buchfelder, M.; Kuwert, T.; Dörfler, A.; Nimsky, C.; Ganslandt, O. Classification of Peritumoral Fiber Tract Alterations in Gliomas Using Metabolic and Structural Neuroimaging. *J. Neurol. Med.* 2011, 52, 1227–1234. [CrossRef] [PubMed]

22. Roberts, T.P.L.; Liu, F.; Kassner, A.; Mori, S.; Guha, A. Fiber Density Index Correlates with Reduced Fractional Anisotropy in White Matter of Patients with Glioblastoma. *AJNR Am. J. Neuroradiol.* 2005, 26, 2183–2186. [PubMed]

23. Del Bene, M.; Östö, D.; Faletti, S.; Bezouwenko, G.V.; DiMeco, F.; Pelicci, G. Extracellular Vesicles: The Key for Precision Medicine in Glioblastoma. *Neuro-Oncology* 2021, 24, 184–196. [CrossRef] [PubMed]

24. Lao, J.; Chen, Y.; Li, Z.-C.; Li, Q.; Zhang, J.; Liu, J.; Zhai, G. A Deep Learning-Based Radiomics Model for Prediction of Survival in Brain Tumor Res. Treat. 2016, 4, 100–106. [CrossRef]

25. Wen, P.Y.; Reardon, D.A. Neuro-Oncology in 2015: Progress in Glioma Diagnosis, Classification and Treatment. *Nat. Rev. Neurol.* 2016, 12, 69–70. [CrossRef]

26. Berghoff, A.S.; Rajky, O.; Winkler, F.; Bartsch, R.; Furtner, J.; Hainfellner, J.A.; Goodman, S.L.; Weller, M.; Schittenhelm, J.; Preusser, M. Invasion Patterns in Brain Metastases of Solid Cancers. *Neuro-Oncology* 2013, 15, 1664–1672. [CrossRef]

27. Siam, L.; Bleckmann, A.; Chaung, H.-N.; Mohr, A.; Klemm, F.; Barrantes-Freer, A.; Blazquez, R.; Wolff, H.A.; Lüke, F.; Rohde, V.; et al. The Metastatic Infiltration at the Metastasis/Brain Parenchyma-Interface Is Very Heterogeneous and Has a Significant Impact on Survival in a Prospective Study. *Oncotarget* 2015, 6, 29254–29267. [CrossRef] [PubMed]

28. Belli, G.; Busoni, S.; Ciccarone, A.; Coniglio, A.; Esposito, M.; Giannelli, M.; Mazzoni, L.N.; Nocetti, L.; Sghedoni, R.; Tarducci, R.; et al. Quality Assurance Multicenter Comparison of Different MR Scanners for Quantitative Diffusion-Weighted Imaging. *J. Magn. Reson. Imaging* 2016, 43, 213–219. [CrossRef]

29. Nestler, U.; Lutz, K.; Pichlmeyer, U.; Stummer, W.; Franz, K.; Reulen, H.-J.; Bink, A.; on behalf of the 5-ALA Glioma Study Group. Anatomic Features of Glioblastoma and Their Potential Impact on Survival. *Acta Neurochir.* 2015, 157, 179–186. [CrossRef]

30. Barz, M.; Gerhardt, J.; Bette, S.; Aftah, A.K.; Huber, T.; Combs, S.E.; Yang, Y.-M.; Wiestler, B.; Skardelly, M.; Gepfner-Tuma, I.; et al. Prognostic Value of Tumour Volume in Patients with a Poor Karnofsky Performance Status Scale – a Bicentric Retrospective Study. *BMCMed. 2021, 21, 446. [CrossRef]

31. Kallenberg, K.; Goldmann, T.; Menke, J.; Strik, H.; Bock, H.C.; Stockhammer, F.; Buhk, J.H.; Frahm, J.; Dechent, P.; Knauth, M. Glioma Infiltration of the Corpus Callosum: Early Signs Detected by DTI. *J. Neurooncol.* 2013, 112, 217–222. [CrossRef]

32. Stadlbauer, A.; Hammes, T.; Grummich, P.; Buchfelder, M.; Kuwert, T.; Dörfler, A.; Nimsky, C.; Ganslandt, O. Classification of Peritumoral Fiber Tract Alterations in Gliomas Using Metabolic and Structural Neuroimaging. *J. Neurol. Med.* 2011, 52, 1227–1234. [CrossRef] [PubMed]

33. Klimas, A.; Drzazga, Z.; Kluczewska, E.; Hartel, M. Regional ADC Measurements during Normal Brain Aging in the Clinical Range of b Values: A DWI Study. *Acta Neurochir.* 2021, 163, 637–644. [CrossRef] [PubMed]

34. Löbel, U.; Sedlack, J.; Reddick, W.E.; Kocak, M.; Ji, Q.; Bronisner, A.; Hillenbrand, C.M.; Patay, Z. Quantitative Diffusion-Weighted and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Analysis of T2 Hypointense Lesion Components in Pediatric Diffuse Intrinsic Pontine Glioma. *AJNR Am. J. Neuroradiol.* 2011, 32, 315–322. [CrossRef] [PubMed]

35. Naganawa, S.; Sato, K.; Katagiri, T.; Mimura, T.; Ishigaki, T. Regional ADC Values of the Normal Brain: Differences Due to Age, Gender, and Laterality. *Eur. Radiol.* 2003, 13, 6–11. [CrossRef] [PubMed]

36. Sener, R.N. Diffusion MRI: Apparent Diffusion Coefficient (ADC) Values in the Normal Brain and a Classification of Brain Disorders Based on ADC Values. *Comput. Med. Imaging Graph.* 2001, 25, 299–326. [CrossRef] [PubMed]

37. Mori, S.; van Zijl, P.C.M. Fiber Tracking: Principles and Strategies—A Technical Review. *NMR Biomed.* 2002, 15, 468–480. [CrossRef] [PubMed]
38. Oishi, K.; Zilles, K.; Amunts, K.; Faria, A.; Jiang, H.; Li, X.; Akhter, K.; Hua, K.; Woods, R.; Toga, A.W.; et al. Human Brain White Matter Atlas: Identification and Assignment of Common Anatomical Structures in Superficial White Matter. *NeuroImage* **2008**, *43*, 447–457. [CrossRef]

39. Vassal, F.; Schneider, F.; Boutet, C.; Jean, B.; Sonthheimer, A.; Lemaire, J.-J. Combined DTI Tractography and Functional MRI Study of the Language Connectome in Healthy Volunteers: Extensive Mapping of White Matter Fascicles and Cortical Activations. *PLoS ONE* **2016**, *11*, e0152614. [CrossRef]

40. Liebel, U.; Sedlack, J.; Güllmar, D.; Kaiser, W.; Reichenbach, J.; Mentzel, H.-J. Diffusion Tensor Imaging: The Normal Evolution of ADC, RA, FA, and Eigenvalues Studied in Multiple Anatomical Regions of the Brain. *Neuroradiology* **2009**, *51*, 253–263. [CrossRef]

41. Lawrenz, M.; Brassen, S.; Finsterbusch, J. Microscopic Diffusion Anisotropy in the Human Brain: Reproducibility, Normal Values, and Comparison with the Fractional Anisotropy. *NeuroImage* **2015**, *109*, 283–297. [CrossRef] [PubMed]

42. O’Donnell, L.J.; Westin, C.-F. An Introduction to Diffusion Tensor Image Analysis. *Neurops. Clin. N. Am.* **2011**, *22*, 185–196. [CrossRef] [PubMed]

43. Fortin, J.-P.; Parker, D.; Tunc, B.; Watanabe, T.; Elliott, M.A.; Ruparel, K.; Roalf, D.R.; Satterthwaite, T.D.; Gur, R.C.; Gur, R.E.; et al. Harmonization of Multi-Site Diffusion Tensor Imaging Data. *NeuroImage* **2017**, *161*, 149–170. [CrossRef] [PubMed]

44. Chaudhary, R.; Morris, R.J.; Steinson, E. The Multifactorial Roles of Microglia and Macrophages in the Maintenance and Progression of Glioblastoma. *J. Neuroimmunol.* **2021**, *357*, 577633. [CrossRef]

45. Miles, K.A. Tumour Angiogenesis and Its Relation to Contrast Enhancement on Computed Tomography: A Review. *Eur. J. Radiol.* **1999**, *30*, 198–205. [CrossRef]

46. Prada, F.; Vitale, V.; Del Bene, M.; Boffano, C.; Sconfienza, L.M.; Pinzi, V.; Mauri, G.; Solbiati, L.; Sakas, G.; Kolev, V.; et al. Contrast-Enhanced MR Imaging versus Contrast-Enhanced US: A Comparison in Glioblastoma Surgery by Using Intraoperative Fusion Imaging. *Radiology* **2017**, 285, 242–249. [CrossRef]

47. Chiang, I.C.; Kuo, Y.-T.; Lu, C.-Y.; Yeung, K.-W.; Lin, W.-C.; Sheu, F.-O.; Liu, G.-C. Distinction between High-Grade Gliomas and Solitary Metastases Using Peritumoral 3-T Magnetic Resonance Spectroscopy, Diffusion, and Perfusion Imagings. *Neuroradiology* **2004**, *46*, 619–627. [CrossRef]

48. Toh, C.H.; Siow, T.Y.; Castillo, M. Peritumoral Brain Edema in Metastases May Be Related to Glymphatic Dysfunction. *Front. Oncol.* **2021**, *11*, 725354. [CrossRef]

49. Martin-Noguerol, T.; Mohan, S.; Santos-Armentia, E.; Cabrera-Zubizarreta, A.; Luna, A. Advanced MRI Assessment of Non-Enhancing Peritumoral Signal Abnormality in Brain Lesions. *Eur. J. Radiol.* **2021**, *143*, 109900. [CrossRef]

50. Zenonos, G.; Friedlander, R.M. Diffusion Weighted Imaging: What Are We Really Seeing? *Neurosurgery* **2010**, *67*, N26–N29. [CrossRef]

51. Noell, S.; Ritz, R.; Wolburg-Buchholz, K.; Wolburg, H.; Fallier-Becker, P. An Allograft Glioma Model Reveals the Dependence of Aquaporin-4 Expression on the Brain Microenvironment. *PLoS ONE* **2012**, *7*, e36555. [CrossRef] [PubMed]

52. Field, A.S.; Alexander, A.L.; Wu, Y.-C.; Hasan, K.M.; Witwer, B.; Badie, B. Diffusion Tensor Eigenvector Directional Color Imaging Patterns in the Evaluation of Cerebral White Matter Tracts Altered by Tumor. *J. Magn. Reson. Imaging* **2004**, *20*, 555–562. [CrossRef] [PubMed]

53. Jellison, B.J.; Field, A.S.; Medow, J.; Lazar, M.; Salamat, M.S.; Alexander, A.L. Diffusion Tensor Imaging of Cerebral White Matter: A Pictorial Review of Physics, Fiber Tract Anatomy, and Tumor Imaging Patterns. *Am. J. Neuroradiol.* **2004**, *25*, 356–369. [PubMed]

54. Chong, S.T.; Liu, X.; Kao, H.-W.; Lin, C.-Y.-E.; Hsu, C.-C.H.; Kung, Y.-C.; Kuo, K.-T.; Huang, C.-C.; Lo, C.-Y.Z.; Li, Y.; et al. Exploring Peritumoral Neural Tracts by Using Neurite Orientation Dispersion and Density Imaging. *Front. Neurosci.* **2021**, *15*, 702353. [CrossRef]

55. Oishi, K.; Zilles, K.; Amunts, K.; Faria, A.; Jiang, H.; Li, X.; Akhter, K.; Hua, K.; Woods, R.; Toga, A.W.; et al. Human Brain White Matter Atlas: Identification and Assignment of Common Anatomical Structures in Superficial White Matter. *NeuroImage* **2008**, *43*, 447–457. [CrossRef]

56. Jütten, K.; Mainz, V.; Gauggel, S.; Patel, H.J.; Binkofski, F.; Wiesmann, M.; Clusmann, H.; Na, C.-H. Diffusion Tensor Imaging Reveals Microstructural Heterogeneity of Normal-Appearing White Matter and Related Cognitive Dysfunction in Glioma Patients. *Front. Oncol.* **2019**, *9*, 536. [CrossRef]

57. Sternberg, E.J.; Lipton, M.L.; Burns, J. Utility of Diffusion Tensor Imaging in Evaluation of the Peritumoral Region in Patients with Primary and Metastatic Brain Tumors. *AJNR Am. J. Neuroradiol.* **2014**, *35*, 439–444. [CrossRef]

58. Jones, D.K.; Knösche, T.R.; Turner, R. White Matter Integrity, Fiber Count, and Other Fallacies: The Do’s and Don’ts of Diffusion MRI. *NeuroImage* **2013**, *73*, 239–254. [CrossRef]

59. Monga, V.; Jones, K.; Chang, S. Clinical relevance of molecular markers in gliomas. *Rev. Médica Clínica Condes* **2017**, *28*, 343–351. [CrossRef]

60. Geraghty, B.J.; Dasgupta, A.; Sandhu, M.; Malik, N.; Maralani, P.J.; Detsky, J.; Tseng, C.-L.; Soliman, H.; Myrehaug, S.; Husain, Z.; et al. Predicting Survival in Patients with Glioblastoma Using MRI Radiomic Features Extracted from Radiation Planning Volumes. *J. Neurooncol.* **2022**, *156*, 579–588. [CrossRef]

61. Śledzińska, P.; Bebyn, M.G.; Furtak, J.; Kowalewski, J.; Lewandowska, M.A. Prognostic and Predictive Biomarkers in Gliomas. *Int. J. Mol. Sci.* **2021**, *22*, 10373. [CrossRef] [PubMed]
62. de Causans, A.; Carré, A.; Roux, A.; Tauziède-Espariat, A.; Ammari, S.; Dezamis, E.; Dhermain, F.; Reuzé, S.; Deutsch, E.; Oppenheim, C.; et al. Development of a Machine Learning Classifier Based on Radiomic Features Extracted from Post-Contrast 3D T1-Weighted MR Images to Distinguish Glioblastoma From Solitary Brain Metastasis. Front. Oncol. 2021, 11, 2577. [CrossRef] [PubMed]

63. Carré, A.; Klausner, G.; Edjlali, M.; Lerousseau, M.; Briend-Diop, J.; Sun, R.; Ammari, S.; Reuzé, S.; Alvarez Andres, E.; Estienne, T.; et al. Standardization of Brain MR Images across Machines and Protocols: Bridging the Gap for MRI-Based Radiomics. Sci. Rep. 2020, 10, 12340. [CrossRef] [PubMed]

64. Lerma-Usabiaga, G.; Mukherjee, P.; Ren, Z.; Perry, M.L.; Wandell, B.A. Replication and Generalization in Applied Neuroimaging. NeuroImage 2019, 202, 116048. [CrossRef]